TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

M E Robson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.